Morbidity and mortality have been reduced significantly in HF patients with the induction of quadruple therapy, consisting of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), a beta-blocker, a mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter-2 (SGLT2) inhibitor [2,3]. Here, SLC5A2 is linked to hydrops fetalis.